Beneficial Impact of Orange Juice Consumption on Risk Factors Associated With Cardiovascular Diseases (CITRUS)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02479568 |
|
Recruitment Status : Unknown
Verified June 2016 by Technological Centre of Nutrition and Health, Spain.
Recruitment status was: Recruiting
First Posted : June 24, 2015
Last Update Posted : June 6, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Cardiovascular Risk Factors | Dietary Supplement: Control Dietary Supplement: 100% Florida OJ Dietary Supplement: 100% Florida OJ-enriched | Phase 3 |
The aim of this study is to compare the effect of different doses of hesperidin in 100% Florida orange juice (OJ) when regularly or postprandially consumed on cardiovascular risk markers; in addition, the plausible role and mechanism of the hesperidin will be investigated.
The sample size was calculated using a previously available bibliography using systolic blood pressure (SBP) as the primary outcome measure. A total of 84 subjects per study product group were needed, assuming variance components of approximately 20.0, to detect differences between the three groups (control, orange juice and hesperidin-enriched orange juice (10 mm Hg)) with a bilateral significance level of α=0.05 and a power of 80 %.
The sample size was computed to be sufficient to detect differences between treatment groups regarding the evolution in time of SBP levels. Justification of chosen sample size is based on the clinically meaningful difference assigned to δ=10.0 mm Hg, which is equivalent to a difference of approximately 7.4 % in patients with baseline SBP levels of approximately 135 mm Hg. Thus, a sample of 252 participants can be used for the chronic three arm parallel trial design (84 subjects/arm) and will allow us to detect small but clinically relevant differences between the three groups with statistical robustness and direct interpretation in terms of the chronic treatment effect.
To the acute postprandial tests, the investigators have chosen n=20 subjects per arm according to the most studies that have addressed the metabolic effects of a postprandial intervention have been performed using a very similar number of subjects with statistically good quality results.
The statistical analysis will follow the principles specified in the guidelines of the ICHE9 and CPMP/EWP/908/99 ICHE9 Points to Consider on Multiplicity Issues in Clinical Trials.
The continuous efficacy variables will be analyzed by an ANCOVA (analysis of covariance) with the baseline value as a covariate.
The efficacy outcomes will be determined using the absolute values and absolute differences from the baseline. The efficacy analysis will be performed using the Available Data Only approach. In addition, the analysis of the primary efficacy variable will be performed with the Baseline Observation Carried Forward approach.
A suitable hypothesis test will be applied to the rest of the variables according to the nature of each variable, such as the Fisher exact test for categorical variables, Student's T-test for continuous variables and Mann-Whitney U test for ordinal scale variables.
The statistical tests will be applied with an α=0.05 two-sided significance level. Post-hoc analyses and comparisons between pairs of groups will be done as for exploratory purposes.
In addition, the statistical plan will be transferred to the application form of the electronic data collection report (e-CDR), which allows the improvement of data management, diminishes human errors (according threshold values of each outcome) and, overall, guarantees the maximum exploitation of human data in the context of statistical analysis.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 252 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Prevention |
| Official Title: | Randomized, Parallel and Double Blind Placebo-controlled Study for the Evaluation of Both Acute and Chronic Role of Hesperidin Consumption in 100% Orange Juice |
| Study Start Date : | September 2015 |
| Estimated Primary Completion Date : | May 2017 |
| Estimated Study Completion Date : | January 2018 |
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: Control
Control drink (placebo)
|
Dietary Supplement: Control
500 mL (250 mL; 2 times/day) of placebo drink for 12 weeks |
|
Experimental: Natural Florida orange juice
100% Florida orange juice (OJ) (natural content of hesperidin)
|
Dietary Supplement: 100% Florida OJ
500 mL (250 mL; 2 times/day) of 100% Florida OJ for 12 weeks |
|
Experimental: Enriched Florida orange juice
100% Florida orange juice (OJ) (enriched hesperidin content)
|
Dietary Supplement: 100% Florida OJ-enriched
500 mL (250 mL; 2 times/day) of 100% Florida OJ-enriched for 12 weeks |
- Systolic Blood Pressure [ Time Frame: Every 2 weeks for a total of 12 weeks. ]During each visit, SBP will be measured after 5 min in a seated position in a comfortable room by the physician. The measurement will be taken in duplicate at 1-min intervals using an automatic sphygmomanometer (OMRON HEM-907; Peroxfarma, Barcelona, Spain), and the average of the two measurements will be calculated.
- Diastolic Blood Pressure [ Time Frame: Every 2 weeks for a total of 12 weeks. ]During each visit, diastolic BP will be measured after 5 min in a seated position in a comfortable room by the physician. The measurement will be taken in duplicate at 1-min intervals using an automatic sphygmomanometer (OMRON HEM-907; Peroxfarma, Barcelona, Spain), and the average of the two measurements will be calculated.
- Ischemic reactive hyperemia (IRH) [ Time Frame: Every 4 weeks for a total of 12 weeks ]The endothelial-dependent vasomotor functions will be measured as IRH by a Laser-Doppler linear Periflux 5000 flowmeter (Perimed AB, Järfälla, Stockholm, Sweden)
- Platelet aggregation [ Time Frame: Every 4 weeks for a total of 12 weeks ]Multiplate analyzer, Roche
- Homocysteine [ Time Frame: Every 4 weeks for a total of 12 weeks ]Homocysteine concentrations will be measured by liquid chromatography-mass spectrometry (LC-MS/MS)
- C-reactive protein (inflammatory marker) [ Time Frame: Every 4 weeks for a total of 12 weeks ]High sensitivity C-reactive protein (hsCRP) by standardized methods in a Cobas Mira Plus autoanalyzer (Roche Diagnostics Systems, Madrid, Spain)
- oxidized LDL (as oxidative stress biomarker) [ Time Frame: Every 4 weeks for a total of 12 weeks ]Mercodia Oxidized LDL ELISA kit will be used to measure the oxidized LDL (mU/L).
- Transcriptomics [ Time Frame: At week 0 (V1) and 12 week (V7). ]Plasma collected at 0 h (V1 and V7) of 20 samples each arm (volunteers in the postprandial study). These cells will be used to perform transcriptomics analysis to detect whole gene expression changes due to the chronic consumption of two doses of hesperidin in 100% Florida orange juice.
- Non-targeted Metabolomics [ Time Frame: At week 0 (V1) and 12 week (V7). ]Plasma collected at 0 h (V1 and V7) of 20 samples each arm (volunteers in the postprandial study) will be used to perform non-targeted metabolomics by Nuclear Magnetic Response Spectroscopy (NMR) to detect metabolomic profile changes due to the chronic consumption of two doses of hesperidin in 100% Florida orange juice
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Inclusion criteria
- Men or women 18-65 years old
- No evidence of chronic disease
- No familial CVD history
- Written informed consent provided before the initial screening visit.
- Blood pressure (with no drug intervention) >120 mm Hg systolic blood pressure ≤ 159 mmHg
Exclusion criteria
- Body mass index (BMI) ≥ 35 kg/m2
- Glucose >125 mg/dl
- Systolic blood pressure ≥ 160 mm Hg and diastolic blood pressure >100 mm Hg or taking antihypertensive medications
- Total cholesterol >240 mg/dl
- LDL-cholesterol >160 md/dl
- TAG >350
- Smoking
- Pregnant or intending to become pregnant
- Use of medications, antioxidants, or vitamin supplements
- Chronic alcoholism
- Intense physical activity (5h/week)
- Intestinal disorders
- Following of a vegetarian diet
- Anemia (hemoglobin ≤13 g/dL in men and ≤12 g/dL in women)
- Current or past participation in a clinical trial or consumption of a research product in the 30 days prior to inclusion in the study
- Failure to follow the study guidelines.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02479568
| Contact: Rosa Maria Valls, PhD | +34 636 944 723 | estudis@ctns.cat | |
| Contact: Anna Pedret, PhD | +34 977 75 93 77 | estudis@ctns.cat |
| Spain | |
| Technological Centre of Nutrition and Health (CTNS) | Recruiting |
| Reus, Tarragona, Spain, 43204 | |
| Contact: Rosa Maria Valls, PhD +34 636 944 723 estudis@ctns.cat | |
| Contact: Ignasi Papell, BSc +34 977 300 431 estudis@ctns.cat | |
| Principal Investigator: | Rosa Solà Alberich, Prof, MD | • University Rovira i Virgili / Hospital Universitari Sant Joan de Reus |
| Responsible Party: | Technological Centre of Nutrition and Health, Spain |
| ClinicalTrials.gov Identifier: | NCT02479568 |
| Other Study ID Numbers: |
CITRUS 14-12 |
| First Posted: | June 24, 2015 Key Record Dates |
| Last Update Posted: | June 6, 2016 |
| Last Verified: | June 2016 |
|
Cardiovascular disease biomarkers transcriptomics orange juice |
hesperidin systolic blood pressure metabolomics cardiovascular risk factor |
|
Cardiovascular Diseases |